Skip Nav Destination
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results
Prebiotic fiber enteral supplementation after allogeneic transplantation: feasibility and impact on the microbiome
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis
Long-term outcomes of patients with refractory cytopenia of childhood under observation only
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis
A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
Platelet-activating histone/antihistone IgG complexes in anti-PF4–negative thrombosis and thrombocytopenia syndrome
Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy
Issue Archive
Table of Contents
INSIDE BLOOD ADVANCES
SYSTEMATIC REVIEW
CLINICAL TRIALS AND OBSERVATIONS
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
Clinical Trials & Observations
Amy E. DeZern,Sylvain Thepot,Stephane de Botton,Andrea Patriarca,Dries Deeren,Jose-Miguel Torregrossa-Diaz,Giovanni Marconi,Teresa Bernal,Juan Bergua Burgues,Blanca Xicoy,Anna Jonášová,Amer M. Zeidan,Sophie Dimicoli-Salazar,Célestine Simand,David Valcarcel,Maria Diez Campelo,Wanxing Chai-Ho,Lalit Saini,Alice Garnier,Klaus Geissler,Yishai Ofran,Zsolt Nagy,Pramila Krishnamurthy,Michael Lübbert,Grzegorz Basak,Hetty E. Carraway,David A. Sallman,Uma Borate,Valeria Santini,Victoria Campbell,Pierre Fenaux,Thorsten Braun,Francesco Lanza,Jan Maciej Zaucha,David A. Roth,Sofia Paul,Pourab Roy,Michael J. Kelly,Angela Volkert,Jaime Chisholm,Tanya Abdul Malak,Virginia M. Klimek,Thomas Cluzeau,on behalf of the Tamibarotene MDS Investigator Group
Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results
Clinical Trials & Observations
Mazyar Shadman,John M. Burke,Jennifer Cultrera,Habte A. Yimer,Syed F. Zafar,Jamal Misleh,Subramanya S. Rao,Charles M. Farber,Aileen Cohen,Hui Yao,Adam Idoine,Qi An,Ian W. Flinn,Jeff P. Sharman
Prebiotic fiber enteral supplementation after allogeneic transplantation: feasibility and impact on the microbiome
Clinical Trials & Observations
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis
Clinical Trials & Observations
David M. Ross,Florian H. Heidel,Andrew Charles Perkins,Andreas Reiter,Carl Crodel,Caroline Riley,María Teresa Gómez-Casares,Istvan Takacs,Heiko Becker,Thomas Lehmann,Olga Vinogradova,Kate Burbury,Alessandro M. Vannucchi,Vikas Gupta,Marielle Wondergem,Jean-Jacques Kiladjian,Grace Cleary,Angela Zhang,Jagannath Kota,Anirudh Prahallad,Monika Wroclawska,Min Lu,Claire N. Harrison
Long-term outcomes of patients with refractory cytopenia of childhood under observation only
Clinical Trials & Observations
Beatrice Drexler,Stephan Schwarz-Furlan,Irith Baumann,Martina Rudelius,Peter Nöllke,Dirk Lebrecht,Senthilkumar Ramamoorthy,Natalia Rotari,Axel Karow,Shinsuke Hirabayashi,Fabian Beier,Yvonne Lisa Behrens,Gudrun Göhring,Reinhard Kalb,Marcin W. Wlodarski,Brigitte Strahm,Miriam Erlacher,Charlotte M. Niemeyer,Ayami Yoshimi
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis
Clinical Trials & Observations
Eli Muchtar,Angela Dispenzieri,Francis K. Buadi,Prashant Kapoor,David Dingli,Taxiarchis V. Kourelis,Wilson Gonsalves,Nelson Leung,Suzanne R. Hayman,Martha Q. Lacy,Mustaqeem Siddiqui,Joselle Cook,Nadine Abdallah,Moritz Binder,Saurabh Zanwar,William Hogan,Rahma Warsame,S. Vincent Rajkumar,Shaji K. Kumar,Morie A. Gertz
A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept
Clinical Trials & Observations
Divya Koura,Kaitlyn Dykes,Aaron Goodman,Caitlin Costello,Carolyn Mulroney,James K. Mangan,Tiffany N. Tanaka,Edward D. Ball,Ayad Hamdan,Ah-Reum Jeong,James Mirocha,Qingyang Zhang,Paula Ogrodnik,Kimberly McConnell,Joseph J. Maroge,Michelle Padilla,Gerald P. Morris,Dimitrios Tzachanis
IMMUNOBIOLOGY AND IMMUNOTHERAPY
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement
Ibrahim N. Muhsen,Gregory W. Roloff,Rawan Faramand,Tamer Othman,Yannis Valtis,Noam E. Kopmar,Simone E. Dekker,Matthew Connor,Santiago Mercadal,Timothy E. O'Connor,Kaitlyn C. Dykes,Mohamed Ahmed,Nikeshan Jeyakumar,Amy Zhang,Katharine Miller,Katherine C. Sutherland,Caitlin Guzowski,Vishal K. Gupta,Navneet Majhail,Minoo Battiwalla,Melhem M. Solh,Shahbaz A. Malik,John Mathews,Caspian H. Oliai,Paul Shaughnessy,Luke Mountjoy,Catherine J. Lee,Aaron C. Logan,Stephanie B. Tsai,Jessica T. Leonard,Marc Schwartz,Joshua P. Sasine,Muthu Kumaran,Noelle Frey,Jae H. Park,Divya Koura,Ryan D. Cassaday,Bijal D. Shah,Ibrahim Aldoss,Lori S. Muffly,LaQuisa C. Hill
Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma
Jan H. Frenking,Xiang Zhou,Kai Rejeski,Vivien Wagner,Patrick Costello,Thomas Hielscher,Lilan Gatti,Joseph Kauer,Omar Nadeem,Elias K. Mai,Christian S. Michel,Mirco J. Friedrich,David Sedloev,Niels Weinhold,Hartmut Goldschmidt,Klaus Herfarth,Anita Schmitt,Michael Hundemer,Michael Schmitt,Carsten Müller-Tidow,Max Topp,Hermann Einsele,Peter Dreger,Nikhil C. Munshi,Adam S. Sperling,Leo Rasche,Sandra Sauer,Marc S. Raab
LYMPHOID NEOPLASIA
Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders
Ángel Serna,Víctor Navarro,Moraima Jiménez,Josu Iraola-Truchuelo,Marc Bosch,Cristina García,Anna Falcó,Adaia Albasanz,Isabel Ruiz-Camps,Cristina Andrés,Andrés Antón,Juliana Esperalba,Ainara Ferrero,Tomás García,Cecilia Carpio,Marta Crespo,Gloria Iacoboni,Ana Marín-Niebla,Francesc Bosch,Pau Abrisqueta
Expression of HERV-K and embryonic genes in chronic lymphocytic leukemia and their association with therapy regimens
Claudia Matteucci,Vita Petrone,Alessandro Giovinazzo,Roberta Laureana,Massimiliano Postorino,Livio Pupo,Chiara Cipriani,Nicola Toschi,Marialaura Fanelli,Antonella Minutolo,Giovangiacinto Paterno,Elisa Buzzatti,Paola Sinibaldi Vallebona,Antonella Zucchetto,Federico Pozzo,Valter Gattei,Giovanni Del Poeta,Adriano Venditti,Emanuela Balestrieri,Maria Ilaria Del Principe
Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas
Josie G. Ford,Min Jung Koh,Alexandra W. Lenart,Caroline MacVicar,Kusha Chopra,Arushi Meharwal,Mark N. Sorial,Mwanasha Merrill,Anna B. Rider,Aliyah R. Sohani,Sean M. McCabe,Ronnie A. Nemec,Makoto Iwasaki,Dhruv Mistry,Khyati Maulik Kariya,Steven Chen,Jeffrey Barnes,Steven McAfee,Yi-Bin Chen,Corben Yuwai Wong,Kristiana Nasto,Eric Jacobsen,Salvia Jain
MYELOID NEOPLASIA
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
Clinical Trials & Observations
Michael J. Mauro,Yosuke Minami,Andreas Hochhaus,Elza Lomaia,Sergey Voloshin,Anna Turkina,Dong-Wook Kim,Jane F. Apperley,Jorge E. Cortes,Andre Abdo,Laura Maria Fogliatto,Dennis Dong Hwan Kim,Philipp le Coutre,Susanne Saussele,Mario Annunziata,Timothy P. Hughes,Naeem Chaudhri,Lynette Chee,Valentin García-Gutiérrez,Koji Sasaki,Carla Boquimpani,Shruti Kapoor,Noemi Espurz,Vishal Dhamal,Delphine Rea
THROMBOSIS AND HEMOSTASIS
Uncovering the role of the Hsp40 family member cysteine string protein-α in mouse platelets
Alexis N. Smith,Hammodah R. Alfar,Smita Joshi,Daniëlle M. Coenen,Joshua Lykins,Isabelle C. Becker,Brittany E. Dong,Harry Chanzu,Chi Peng,Kanakanagavalli Shravani Prakhya,Linda Omali,Irina D. Pokrovskaya,Brian Storrie,Joseph Italiano,Sidney W. Whiteheart
Platelet-activating histone/antihistone IgG complexes in anti-PF4–negative thrombosis and thrombocytopenia syndrome
Clinical Trials & Observations
Max Esefeld,Stefan Handtke,Rainer Kaiser,Leo Nicolai,Lea Di Fina,Dario Rossaro,Jan Wesche,Justina Rath,Ann-Christin Wienrich,Till Hoffmann,Lukas Harasser,Clemens Feistritzer,Lorin Loacker,Kourosh Lotfi,Margareta Holmström,Jovan Antovic,Leif Steil,Uwe Völker,Lena Ulm,Karsten Becker,Nils Olaf Hübner,Andreas Greinacher,Thomas Thiele
TRANSPLANTATION
Allogeneic hematopoietic stem cell transplantation for STAT3 hyper-IgE syndrome: a worldwide study
Christo Tsilifis,Johannes Raedler,Joanna Renke,Michael Medinger,Alexandra Laberko,Ásgeir Haraldsson,Niraj Patel,Peter Ciznar,Melanie Wong,Steven J. Keogh,Paul Gray,Richard Mitchell,Venetia Bigley,Suzanne Elcombe,Fabian Hauck,Michael H. Albert,Eleni Tholouli,Archana Herwadkar,Shuayb Elkhalifa,Chris Kosmidis,Giorgio Callisti,Lauri M. Burroughs,Karin Chen,Ben Carpenter,Thomas A. Fox,Emma C. Morris,Ramya Uppuluri,Revathi Raj,Masakatsu Yanagimachi,Emilie P. Buddingh,Christina Oikonomopoulou,Corina Gonzalez,Dimana Dimitrova,Jennifer A. Kanakry,Danielle Arnold,Sung-Yun Pai,Mary A. Slatter,Mark S. Pearce,Austen Worth,Alexandra F. Freeman,Andrew R. Gennery
RESEARCH LETTERS
Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy
Clinical Trials & Observations
Jessica S. Little,Angelica Medina Pena,E. Bridget Kim,Andrew J. Yee,Omar Nadeem,Shonali Midha,Adam S. Sperling,Nikhil C. Munshi,Noopur Raje,Matthew J. Frigault,Diana D. Cirstea,Sarah P. Hammond
LETTERS TO THE EDITOR
-
Cover Image
Cover Image
Fluorescence image showing IGSF9 (green) which was exclusively localized to the cellular membrane of acute myeloid leukemia (AML) cells with the red portion representing lysosomes. This image validates the therapeutic potential of anti-IGSF9 therapy in AML treatment. The image not only confirms surface expression as a targetable site, but it also establishes benchmarks for antibody-drug conjugate pharmacokinetics, providing support for the development of precision therapies in AML cells. See the article by Hui et al.
Advertisement intended for health care professionals
Advertisement intended for health care professionals
Avoid burning bridges before CAR-T therapy in myeloma